- As a leading healthcare and technology investor, Nordic Capital will further support and accelerate ArisGlobal’s growth
Nordic Capital Fund IX today announced an agreement to acquire US-headquartered ArisGlobal, a leading global provider of innovative SaaS software solutions, which are transforming the way the most successful life sciences companies handle drug safety, clinical development, regulatory compliance, and medical affairs. Drawing on its deep understanding of both the healthcare and technology sectors, Nordic Capital will support ArisGlobal’s continued development. The founders of ArisGlobal will remain as minority shareholders.
ArisGlobal is a visionary technology company that has successfully developed a next-generation platform that uses advanced cognitive computing and machine learning to automate all core functions of drug safety, regulatory compliance and medical affairs. Currently, more than 200 life sciences companies such as AstraZeneca, NovoNordisk, Merck and Novartis, CROs and government health authorities, as well as 40 of the top 50 global biopharmaceutical companies, rely on ArisGlobal’s solutions. Benefiting from deep expertise, longstanding customer relationships and a 30-year track record, ArisGlobal assists clients in maintaining regulatory compliance, managing and mitigating risk, and improving operational efficiency.
ArisGlobal is headquartered in Miami, FL, USA, with regional offices in Europe, India, Japan and China. It has 1,200 employees globally and c. USD 100 million of annual revenues. In recent years, ArisGlobal has invested in transforming its traditional on-premise offering to a hosted solution sold through a SaaS model.
“This transaction is representative of our rapid growth in the global life sciences industry, which is further proven by the adoption of our LifeSphere platform by the U.S. FDA. We look forward to partnering with Nordic Capital to leverage our common vision, values and combined talents to offer the most innovative technology platform to the life science industry. Nordic Capital has extensive experience in the pharma IT market from previous investments, and a proven track-record building strong teams which can further accelerate ArisGlobal’s growth. Nordic Capital also has a long track-record of partnerships with founding families and is well positioned to support our continued growth over the years to come,” says Deepak Abbhi, Founder and Chairman of the Board of ArisGlobal.
“We are now embarking on a new chapter that will accelerate our ability to achieve our mission. Our unwavering focus on our customers’ needs will continue to be the core of who we are as a company. It drives the development of our LifeSphere platform. It fuels our passion for becoming the premier innovative technology company in the world. We share a closely aligned vision with Nordic Capital for the future of the industry and this partnership gives us immediate access to deep resources and expert guidance that will help us in our journey. I am more excited than ever about the future,” says Sankesh Abbhi, President and CEO of ArisGlobal.
“This investment lies at the heart of Nordic Capital’s investment strategy as a leading healthcare and technology investor. We have followed the pharmacovigilance market closely for several years and know the industry well. ArisGlobal has a top-quality management team and its success is based on its commitment to develop leading and innovative cloud-based software that help organisations maintain regulatory compliance, manage and mitigate risk, and improve operational efficiency. ArisGlobal’s SaaS native software is becoming the preferred choice for life sciences companies because it enables them to quickly implement cost-effective solutions for drug safety reporting, regulatory compliance, and medical affairs,” says Daniel Berglund, Principal at the Advisor to the Nordic Capital Funds.
“The US is a key global market for healthcare companies and offers opportunities that are consistent with Nordic Capital’s investment strategy. ArisGlobal is a company that fits well within the portfolio and is well placed to achieve long term growth driven by favourable sector trends such as continued technological and scientific innovation, serving an attractive innovation driven customer base. We look forward to partnering with ArisGlobal where Nordic Capital can deploy its unique combination of capital and strong operational skills to accelerate growth and support positive transformative change.” says Dr Raj Shah, Partner, Co-Head of Healthcare at the Advisor to the Nordic Capital Funds.
The parties have agreed to not disclose any financial details. The transaction is subject to customary regulatory approvals.
Since inception in 1989, Nordic Capital has made 28 healthcare platform investments across Europe and North America and an additional 14 investments in the Technology & Payments sector, supporting active value creation agendas to build industry winners. Previous investments in the US include ERT, a leading provider of high-quality patient safety and efficacy endpoint data collection solutions for use in clinical drug development, and Orchid Orthopedics Solutions, a leader in the design and manufacture of implants to the global orthopaedic market.
The investment in ArisGlobal coincides with the Advisor to the Nordic Capital Funds expanding into the US, where it will open a permanent office in New York during the Autumnof 2019, building on Nordic Capital’s reputation as a leading investor in global healthcare and already established track record in the US market.
Footnote: “Nordic Capital” or “Nordic Capital Funds” refers to any, or all, Nordic Capital branded or associated funds or investments vehicles and their associated management entities. Nordic Capital is advised by its exclusive advisors, the NC Advisory entities and the Nordic Capital Investment Advisory entities, any or all of which is referred to as the Advisor to the Nordic Capital Funds.
Katarina Janerud, Communications Manager,
The Advisor to the Nordic Capital Funds
Tel: +46 8 440 50 50
Sam Stein, VP, Marketing & Commercial Strategy
ArisGlobal is a visionary technology company that’s transforming the way today’s most successful life sciences companies develop breakthroughs and bring new products to market. ArisGlobal’s LifeSphere® drug development platform integrates cognitive computing technologies to automate the core functions of the product lifecycle. Designed with deep expertise and a long-term perspective that spans more than 30 years, the LifeSphere platform delivers actionable insights, boosts efficiency, ensures compliance, and lowers total cost of ownership through a multi-tenant SaaS model. ArisGlobal is headquartered in Miami, Florida, USA, with regional offices in Europe, India, Japan and China. For more information about ArisGlobal, please visit www.arisglobal.com
About Nordic Capital
Nordic Capital is a leading private equity investor with a resolute commitment to creating stronger, sustainable businesses through operational improvement and transformative growth. Nordic Capital focuses on selected regions and sectors where it has deep experience and a proven track record. Core sectors are Healthcare, Technology & Payments, Financial Services and in addition, Industrial Goods & Services and Consumer. Key regions are the Nordics, Northern Europe and globally for Healthcare. Since inception in 1989, Nordic Capital has invested EUR 14 billion in over 100 investments. The most recent fund is Nordic Capital Fund IX with EUR 4.3 billion in committed capital, principally provided by international institutional investors such as pension funds. The Nordic Capital Funds and vehicles are based in Jersey. They are advised by several advisory entities, which are based in Sweden, Denmark, Finland, Norway, Germany, the UK and the US, any or all of which are referred to as the Advisor to the Nordic Capital Funds. For further information about Nordic Capital, please visit www.nordiccapital.com